Abstract:Background: Celastrol, an important extract of Tripterygium wilfordii , shows strong antitumor activity in a variety of tumors including nasopharyngeal carcinoma (NPC). However, little is known about its targets in NPC. We aimed to screen the key gene targets of Celastrol in the treatment of NPC by means of in silico analyses (including network pharmacology and molecular docking) and experimental evaluations. Methods: The main target genes of Celastrol and the genes related to NPC were obtained by retrieving the relevant biological databases, and the common targets were screened. Protein-protein interaction analysis was used to screen the hub genes. Then, a “compound-target-disease” network model was created and molecular docking was used to predict the binding of Celastrol to the candidate hub proteins. Afterward, the expression changes of the candidate genes under the administration of Celastrol were verified in vitro and in vivo . Results: Sixty genes common to Celastrol and NPC were screened out, which may be related to numerous biological processes such as cell proliferation, apoptosis, and tube development, and enriched in various pathways such as PI3K- Akt, EGFR tyrosine kinase inhibitor resistance, and Apoptosis. The tight binding ability of the candidate hub proteins (TNF, VEGFA, and IL6) to Celastrol was predicted by molecular docking [Docking energy: TNF, −6.08; VEGFA,−6.76; IL6,−6.91(kcal/mol)]. In vitro experiments showed that the expression of TNF and VEGFA decreased while the expression of IL6 increased in NPC cells (CNE2 and HONE1) treated with Celastrol. In vivo experiments suggested that Celastrol significantly reduced the weight and volume of the transplanted tumors in tumor-bearing mice in vivo . The expression of TNF, VEGFA, and IL6 in the transplanted tumor cells could be regulated by using Celastrol, and the expression trends were consistent with the in vitro model. Conclusion: Several gene targets have been filtered out as the core targets of Celastrol in the treatment of NPC, which might be involved in a variety of signaling pathways. Hence, Celastrol may exert its anti-NPC activity through multiple targets and multiple pathways, which will provide new clues for further research. Future experiments are warranted to validate the findings.

Antitumor studies on celastrol and its derivatives as RORα agonists and RORγ inhibitors based on Alphafold reverse docking strategy

Celastrol Suppresses Colorectal Cancer Via Covalent Targeting Peroxiredoxin 1

Discovery, structural optimization, and anti-tumor bioactivity evaluations of betulinic acid derivatives as a new type of RORγ antagonists

Design, Synthesis and Antitumor Evaluation of Novel Celastrol Derivatives

Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy

Discovery of Biaryl Amide Derivatives As Potent, Selective, and Orally Bioavailable RORγt Agonists for Cancer Immunotherapy.

3D-QSAR, molecular docking and molecular dynamics studies of a series of RORγt inhibitors.

Discovery of Aryl-Substituted Indole and Indoline Derivatives As RORγt Agonists

The evolution paths of some reprehensive scaffolds of RORt modulators, a perspective from medicinal chemistry

Design, synthesis, and evaluation of antitumor activity of novel C‐6 sulfhydryl‐substituted and 20‐substituted derivatives of celastrol

Exploration of the effect of Celastrol on protein targets in nasopharyngeal carcinoma: Network pharmacology, molecular docking and experimental evaluations

Design, synthesis of novel celastrol derivatives and study on their antitumor growth through HIF-1α pathway

Discovery of 3-(2-aminobenzo[d]thiazol-5-yl) Benzamide Derivatives As Potent Anticancer Agents Via ROR1 Inhibition

Synthesis and Biological Evaluation of Celastrol Derivatives with Improved Cytotoxic Selectivity and Antitumor Activities

Celastrol Inhibits the Growth of Human Glioma Xenografts in Nude Mice Through Suppressing VEGFR Expression

Celastrol Attenuates the Invasion and Migration and Augments the Anticancer Effects of Bortezomib in a Xenograft Mouse Model of Multiple Myeloma

Synthesis and Characterisation of Celastrol Derivatives As Potential Anticancer Agents

Modes of Action Insights from the Crystallographic Structures of Retinoic Acid Receptor-Related Orphan Receptor-Γt (Rorγt)

Synthesis and Biological Evaluation of Celastrol Derivatives as Potential Immunosuppressive Agents

Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties.

Celastrol is a Novel Selective Agonist of Cannabinoid Receptor 2 with Anti-Inflammatory and Anti-Fibrotic Activity in a Mouse Model of Systemic Sclerosis